Press Releases

FREMONT, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR), a leading supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, today announced it has shipped its first plasma-enhanced chemical vapor deposition (PECVD) silicon carbonitride (SiCN) system to a leading semiconductor manufacturer. As the latest addition to the Saturn Series of the ACM Planetary Family, this system met customer-defined process specifications in ACM's Lingang lab and has been shipped to the customer site for validation. Designed to address advanced back-end-of-line (BEOL) requirements, the system also positions ACM to serve the growi

Coincides with Release of ACM Shanghai First Quarter 2026 ResultsACM Reaffirms 2026 Revenue Outlook FREMONT, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- ACM Research, Inc. ("ACM") (NASDAQ:ACMR), a leading supplier of wafer processing solutions for semiconductor and advanced wafer-level packaging applications, today announced expectations for preliminary unaudited revenue and total shipments for the first quarter of 2026. Today's release coincides with the as-scheduled release of unaudited financial results by ACM Research (Shanghai), Inc., ACM's principal operating subsidiary ("ACM Shanghai"), to the Shanghai Stock Exchange website [link to China Disclosure]. ACM will discuss its

Demand Response Program Targeted to Add USD 1.9 Million in Annualized EBITDA, with No Incremental Capex or Opex Required  Full Year Annualized EBITDA Impact Expected from Fiscal Year 2027 Enrolment in Demand Response Program Complementary to AI Tenant Operations LONDON, April 27, 2026 (GLOBE NEWSWIRE) -- VivoPower PLC (NASDAQ:VIVO) ("VivoPower" or the "Company"), a leading B Corp-certified global developer and owner of powered land and data center infrastructure for AI compute applications, today announced that its 41.5 MW Mo i Rana data center in Northern Norway has prequalified 30 MW of capacity into Statnett SF's ancillary services markets, providing balancing capacity to the Nordi

Quarterly Highlights: Successfully closed acquisition of Presence Bancshares.Completed core system conversion April 13, 2026.Total assets $2.9 billion.Record Net Interest Income of $24.6 million.Tangible Book Value per share $22.43. HONESDALE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Norwood Financial Corp (the "Company") (Nasdaq Global Market-NWFL) the holding company of Wayne Bank, announced results for the first quarter ended March 31, 2026. Jim Donnelly, President and Chief Executive Officer, stated, "We are pleased to announce our first quarter results as they reflect the underlying strength of our franchise and the progress we are making in a challenging operating environment. On a

EINDHOVEN, The Netherlands, April 27, 2026 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ:NXPI) will hold its annual meeting of shareholders on Wednesday, June 10, 2026 at 8:30 a.m. CET at the Company's Headquarters, High Tech Campus 60, 5656 AG, Eindhoven, The Netherlands. NXP has filed its definitive proxy statement and annual report with the U.S. Securities and Exchange Commission and this proxy statement and other related meeting materials are also available at nxp.com/agm. NXP intends to use the notice and access proxy distribution method and expects to distribute the notice of internet availability of proxy materials no later than May 20, 2026. Shareholders may request paper c

Receive a $10 Bonus Card for every $50 in Gift Cards Purchased Online through Mother's Day The Cheesecake Factory® (NASDAQ:CAKE), known for its extensive menu, generous portions and legendary desserts, is making Mother's Day shopping sweeter and easier with a special online gift card offer: For every $50 in Gift Cards purchased online in a single transaction from Monday, April 27, 2026 through Mother's Day, Sunday, May 10, 2026, guests will receive a complimentary $10 Bonus Card redeemable May 11, 2026 through June 3, 2026*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427648479/en/The Cheesecake Factory celebrates Mother

Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient population with no FDA-approved therapies SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways, today announced that a Type C meeting with the U.S. Food and Drug Administration ("FDA") has resulted in alignment on the design of a pivotal clinical st

Company marks a decade of channel-first commitment, partner growth, and customer-centric innovation Zebra Technologies Corporation (NASDAQ:ZBRA), a global leader in digitizing and automating workflows to deliver intelligent operations, today is celebrating the 10th anniversary of its Zebra™ PartnerConnect program. Zebra launched the program in 2016, unifying its global channel partners under a single, comprehensive program designed to foster growth, profitability, and success for the entire ecosystem. For a decade, Zebra has demonstrated an unwavering commitment to its more than 10,000 active channel partners globally. The PartnerConnect program provides a proven model for partner advan

Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa which is already approved for intravenous (IV) inductionNORTH CHICAGO, Ill., April 27, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease (CD). "Crohn's disease is a chronic inflammatory condition that affects an estimated 1 million Americans, and its impact often reac

Traeger, Inc. ("Traeger" or the "Company") (NYSE:COOK), creator and category leader of the wood pellet grill, today announced that it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 4:30 p.m. Eastern Time to discuss its financial results. Those who wish to participate in the call may do so by dialing (833) 461-5787 or +1 (585) 542-9983 for international callers, conference ID 832752707. To pre-register for the conference call, please visit Traeger First Quarter 2026 Earnings Conference Call. The conference call will also be webcast live at https://investors.traeger.com. For those unable to partic

Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 days of continuous, uninterrupted monitoring with Zio® ambulatory ECG devices to reduce missed arrhythmias and provide a more complete assessment of arrhythmia burden, including in post-ablation and pregnancy populations.1-2Findings raise important considerations for post-ablation anticoagulation decisions based on prior studies such as the OCEAN trial that relied on short-duration (24–48-hour) monitoring, as these data show this approach would miss AF recurrence in 26% of patients.1 SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdin

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to TERN-701, a novel, oral allosteric BCR::ABL1 inhibitor, for the treatment of adult patients with Ph+ CML in the chronic phase without the T315I mutation previously treated with two or more TKIs. "There remains an urgent need for CML treatments that offer improved efficacy, safety, and tolerability over current therapies," said Scott Harris, chief development and operations officer at Terns. "This designation from the FDA su

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia, a life-threatening disease in which pathogenic immunoglobulin G autoantibodies attach to and destroy red blood cells, leading to debilitating anemiaIMAAVY is designed to target the underlying cause of warm autoimmune hemolytic anemia by reducing circulating immunoglobulin G, including autoantibodies, while preserving critical immune functions Pivotal study showed rapid and durable hemoglobin responsea and fatigue improvementb compared to placebo in patients with warm autoimmune hemolytic anemiaSPRING HOUSE, Pa., April 27, 202

BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced cancers, today announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the signing of a sponsored research agreement (SRA) with Michigan State University (MSU). Dr. Moore, Associate Dean for Research Development, Director of the Precision Health Program and Professor in the Departments of Radiology and Physiology at Michigan State University, is a

BATON ROUGE, La. , April 27, 2026 (GLOBE NEWSWIRE) -- Business First Bancshares, Inc. (NASDAQ:BFST) (Business First), parent company of b1BANK, today announced its unaudited results for the quarter ended March 31, 2026. Business First reported net income available to common shareholders of $22.2 million or $0.68 per diluted common share, an increase of $1.2 million and a decrease of $0.03, respectively, compared to the linked quarter. On a non-GAAP basis, core net income for the quarter ended March 31, 2026, which excludes certain income and expenses, was $24.0 million or $0.73 per diluted common share, an increase of $0.5 million and a decrease of $0.06 from the linked quarter. The quarte

PWM Wealth Tech Awards recognize RBC's strategy of pairing top-tier advisors with intelligent technology to drive growth and client outcomesTORONTO, April 27, 2026 /CNW/ - RBC Wealth Management, Canada's largest full-service wealth management firm, has won two prestigious awards at the PWM Wealth Tech Awards, securing Best Private Bank for Digitally Empowering Relationship Managers in Canada and Best Private Bank for Use of Technology in Canada, for its capabilities across RBC's Canadian wealth management and private banking businesses. These awards recognize RBC's leadership in

HALLANDALE BEACH, Fla., April 27, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that on April 27, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). As a result, the matter has been closed.

CLEVELAND, April 27, 2026 /PRNewswire/ -- Avient Corporation (NYSE:AVNT), an innovator of materials solutions, announced today that Giuseppe (Joe) Di Salvo has been promoted and named Senior Vice President and Chief Financial Officer, effective June 1, 2026. He will succeed Jamie A. Beggs, who will be leaving Avient June 1, 2026 to pursue other opportunities. Mr. Di Salvo brings 25 years of financial experience, including nearly 15 years at Avient, with extensive experience in investor relations, accounting, financial planning and analysis, and treasury. This diverse experience

Sierra Bancorp (NASDAQ:BSRR), parent of Bank of the Sierra, today announced its unaudited financial results for the quarter ended March 31, 2026. Sierra Bancorp reported consolidated net income of $12.5 million, or $0.96 per diluted share, for the first quarter of 2026 compared to $9.1 million, or $0.65 per diluted share, in the first quarter of 2025. Highlights for the First Quarter of 2026 (unless otherwise stated): Strong Quarterly Earnings Metrics Diluted earnings per share increased $0.31, or 47%, from the same quarter in 2025. Return on average assets improved to 1.39% compared to 1.02% for the same quarter in 2025. Return on average equity rose to 13.88% compared to 10.4

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract accepted for poster presentation, sharing data on the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and select nutrition biomarkers, at the National Kidney Foundation's (NKF) Spring Clinical Meetings, to be held May 7-10, 2026, in New Orleans. XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chroni